

Hyperandrogenism and Metabolic Syndrome Are Associated With Changes in Serum-Derived microRNAs in Women With Polycystic Ovary Syndrome

Sørensen, Anja Elaine; Bækgaard Udesen, Pernille; Maciag, Grzegorz; Geiger, Julian; Saliani, Negar; Januszewski, Andrzej; Jiang, Guozhi; Ma, Ronald C; Hardikar, Anandwardhan Awadhoot; Wissing, Marie Louise Muff; Mikkelsen, Anne Lis Englund; Dalgaard, Louise Torp

Published in:
Frontiers in Medicine

DOI:
[10.3389/fmed.2019.00242](https://doi.org/10.3389/fmed.2019.00242)

Publication date:
2019

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Sørensen, A. E., Bækgaard Udesen, P., Maciag, G., Geiger, J., Saliani, N., Januszewski, A., Jiang, G., Ma, R. C., Hardikar, A. A., Wissing, M. L. M., Mikkelsen, A. L. E., & Dalgaard, L. T. (2019). Hyperandrogenism and Metabolic Syndrome Are Associated With Changes in Serum-Derived microRNAs in Women With Polycystic Ovary Syndrome. *Frontiers in Medicine*, 6(242), Article 242. <https://doi.org/10.3389/fmed.2019.00242>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact rucforsk@kb.dk providing details, and we will remove access to the work immediately and investigate your claim.



Hyperandrogenism and Metabolic Syndrome Are Associated With Changes in Serum-Derived microRNAs in Women With Polycystic Ovary Syndrome

Anja E. Sørensen^{1,2*}, Pernille B. Udesen^{1,3}, Grzegorz Maciag¹, Julian Geiger¹, Negar Saliani¹, Andrzej S. Januszewski⁴, Guozhi Jiang⁵, Ronald C. Ma⁵, Anandwardhan A. Hardikar⁴, Marie Louise M. Wissing³, Anne Lis M. Englund³ and Louise T. Dalgaard¹

¹ Department of Science and Environment, Roskilde University, Roskilde, Denmark, ² Odense University Hospital, The Danish Diabetes Academy, Odense, Denmark, ³ Fertility Clinic, Department of Gynecology and Obstetrics, Zealand University Hospital, Køge, Denmark, ⁴ Diabetes and Islet Biology Group, NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia, ⁵ Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong

OPEN ACCESS

Edited by:

Giovanni Tarantino,
University of Naples Federico II, Italy

Reviewed by:

Cheng Wang,
Nanjing University, China
Nicolas Crisosto,
University of Chile, Chile

*Correspondence:

Anja E. Sørensen
elaine@ruc.dk

Specialty section:

This article was submitted to
Translational Medicine,
a section of the journal
Frontiers in Medicine

Received: 16 August 2019

Accepted: 14 October 2019

Published: 01 November 2019

Citation:

Sørensen AE, Udesen PB, Maciag G, Geiger J, Saliani N, Januszewski AS, Jiang G, Ma RC, Hardikar AA, Wissing MLM, Englund ALM and Dalgaard LT (2019) Hyperandrogenism and Metabolic Syndrome Are Associated With Changes in Serum-Derived microRNAs in Women With Polycystic Ovary Syndrome. *Front. Med.* 6:242. doi: 10.3389/fmed.2019.00242

Polycystic ovary syndrome (PCOS) remains one of the most common endocrine disorder in premenopausal women with an unfavorable metabolic risk profile. Here, we investigate whether biochemical hyperandrogenism, represented by elevated serum free testosterone, resulted in an aberrant circulating microRNA (miRNAs) expression profile and whether miRNAs can identify those PCOS women with metabolic syndrome (MetS). Accordingly, we measured serum levels of miRNAs as well as biochemical markers related to MetS in a case-control study of 42 PCOS patients and 20 Controls. Patients were diagnosed based on the Rotterdam consensus criteria and stratified based on serum free testosterone levels (≥ 0.034 nmol/l) into either a normoandrogenic ($n = 23$) or hyperandrogenic ($n = 19$) PCOS group. Overall, hyperandrogenic PCOS women were more insulin resistant compared to normoandrogenic PCOS women and had a higher prevalence of MetS. A total of 750 different miRNAs were analyzed using TaqMan Low-Density Arrays. Altered levels of seven miRNAs (miR-485-3p, -1290, -21-3p, -139-3p, -361-5p, -572, and -143-3p) were observed in PCOS patients when compared with healthy Controls. Stratification of PCOS women revealed that 20 miRNAs were differentially expressed between the three groups. Elevated serum free testosterone levels, adjusted for age and BMI, were significantly associated with five miRNAs (miR-1290, -20a-5p, -139-3p, -433-3p, and -361-5p). Using binary logistic regression and receiver operating characteristic curves (ROC), a combination panel of three miRNAs (miR-361-5p, -1225-3p, and -34-3p) could correctly identify all of the MetS cases within the PCOS group. This study is the first to report comprehensive miRNA profiling in different subgroups of PCOS women with respect to MetS and suggests that circulating miRNAs might be useful as diagnostic biomarkers of MetS for a different subset of PCOS.

Keywords: microRNA, polycystic ovary syndrome, serum free testosterone, hyperandrogenism, metabolic syndrome, TaqMan low density arrays

INTRODUCTION

Polycystic ovary syndrome (PCOS) presents with a multifactorial etiology that includes genetic predisposition (1) and environmental factors. PCOS is the most common endocrine disturbance in women and has a prevalence of 6.1–19.9% among women in the reproductive-age (2). According to the Rotterdam criteria, PCOS is diagnosed, when two out of the three following criteria are fulfilled: (1) Oligo- or anovulation, (2) Clinical and/or biochemical signs of hyperandrogenism, and (3) Polycystic ovaries and exclusion of other etiologies (such as congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome) (3–5).

Elevated androgen levels constitute a key feature in the pathogenesis of PCOS (5) with high testosterone (T) levels being linked with abdominal fat distribution (6), glucose intolerance (5), and insulin resistance (5) as well as ovulatory dysfunction (7). Both androstenedione and T contribute to the total circulating androgen pool. A large cohort study of PCOS women showed that elevated free T levels conferred increased metabolic risk compared to PCOS women with isolated increased androstenedione (8). Normoandrogenic oligo- or anovulatory patients with polycystic ovaries often have a milder metabolic profile that more closely resembles that of control subjects (9, 10). The clinical indication of hyperandrogenism, scored by Ferriman Gallwey (FG), varies by ethnicity, sensitivity of the hair follicles to androgens (11) as well as the biochemical level of circulating androgens. Thus, FG-score correlates only modestly with total serum T (12). Furthermore, hyperandrogenemia, but not hirsutism, was found to be an independent predictor of metabolic syndrome (MetS) presence in PCOS patients (13). Given that PCOS women already have an unfavorable metabolic profile in early adulthood, there is a need for PCOS patient stratification in terms of metabolic risk outcomes independently of the different PCOS phenotypes.

Circulating microRNA (miRNA) profiles may constitute valuable screening tools as non-invasive biomarkers as they are abundant in serum, resistant to nucleases and stable over freeze-thaw cycles. Sensitive and specific reverse-transcription polymerase chain reaction (RT-qPCR)-based assays for their detection suggest miRNAs as promising biomarker candidates (14). In cells, miRNAs post-transcriptionally impair mRNA translation and, consequently, a dysregulated miRNA expression profile may affect various cellular processes and pathways, in keeping with the complexity of PCOS (15). Moreover, alterations in the circulating miRNA profile may reflect underlying changes in miRNA expression in or secretion from several tissues.

Research concerning miRNAs in serum of PCOS patients is limited; at the present time, few studies examine this topic (16–24). There is consensus that a miRNA profile has the ability to distinguish between PCOS patients and controls. However, there is only limited agreement on which miRNAs that could serve as markers of PCOS (15), although miR-21 and miR-93 have received attention by several groups as being involved in the pathogenesis of PCOS (25–31). Circulating miRNAs may also (in time, given further investigations) present as valuable informants about various

pathophysiological processes occurring in remote and potentially inaccessible tissues.

In view of these findings, the present study evaluates, in an unbiased and comprehensive fashion, how miRNAs in serum relate with PCOS in Danish women. Furthermore, because of the significant role of hyperandrogenemia in many aspects of PCOS, patients were categorized into biochemical hyperandrogenic or normoandrogenic PCOS groups to discover more precise links between different phenotypes of PCOS and the level of circulating of miRNAs. In this study, we have systematically screened serum miRNAs from 62 study participants using the TaqMan Low-Density Array (TLDA) of 750 different miRNAs and determined their correlation with clinical and metabolic indices found in PCOS women ($n = 42$) compared with age as well as in BMI matched Controls ($n = 20$). Previous studies have used triage-based study designs that investigated RNA from a pool of PCOS patients or only a subset of study participants for TLDA or sequencing, followed by a validation of selected miRNAs by individual RT-qPCR in a larger study sample (16, 32). To our knowledge, this is the first study with a comprehensive screening of an entire PCOS study population for this number of different miRNAs.

MATERIALS AND METHODS

Study Population

During January 2010–February 2013, we recruited 42 women diagnosed with PCOS according to the Rotterdam 2003 criteria and 20 healthy, age, and body mass index (BMI) matched, regular cycling women who were referred to the fertility clinic due to tubal factor infertility or male infertility. For evaluation purposes, PCOS women were subdivided according to high or normal free serum T levels. A PCOS patient with free serum T above 0.034 nmol/l was considered biochemical hyperandrogenic according to Danish reference intervals (95th percentile) for serum free T for females aged 11–50 (33, 34). Further details of the population is given elsewhere (26).

Ethics

This study was approved by the Local Scientific Ethical Committee of Region Zealand, DK (approval no. SJ-156). The study was conducted in accordance with the Helsinki Declaration II and all the participants gave written informed consent before their inclusion.

Baseline Characteristics

Anthropometric and biochemical measurements obtained in this study population have been described previously (26, 35). Serum T, androstenedione, and dehydroepiandrosterone sulfate (DHEAS) were measured by liquid chromatography-tandem mass spectrometry (PerkinElmers Inc., USA), sex hormone binding globulin (SHBG) by an immunometric assay with fluorescence detection on the Abbott Architect i2000 analyzer. Estimation of free serum T was obtained based on SHBG and total T according to Vermeulen et al. (36). Insulin resistance was indirectly assessed using the homeostatic index of insulin resistance (HOMA-IR) index according to this formula: $\text{HOMA-IR} = [\text{Fasting plasma insulin (mU/L)} \bullet \text{Fasting$

plasma glucose (mmol/L)]/22.5. In accordance with current consensus statements (37), Anti-Müllerian hormone (AMH) was not included in the present study. MetS was present if any three of the following criteria was fulfilled according to International Diabetes Federation consensus statement (38): (1) waist circumference ≥ 80 cm, (2) Elevated blood pressure ($\geq 130/85$ mmHg), (3) Raised fasting blood glucose ≥ 5.6 mmol/L, (4) Decreased HDL cholesterol (<1.3 mmol/L), and (5) Increased triglyceride levels (≥ 1.7 mmol/L).

Sample Preparation and Isolation of miRNA From Serum

Total RNA was extracted from serum samples with Tri-reagent LS (Sigma-Aldrich, Brøndby, Denmark), according to manufacturers' protocol and stored at -80°C until analysis. RNA concentration and purity were assessed using a NanoDrop ND-1000 (Thermo Fisher Scientific, Hvidovre, Denmark).

MiRNA Serum Profiling

Megaplex RT-primer pools were used to reverse transcribe 125 ng RNA to cDNA and TaqMan MicroRNA Reverse Transcription Kit (ThermoFisher Scientific) according to manufacturers' protocol. The RT-product was pre-amplified with TaqMan® PreAmp Master Mix and miRNA PreAmp primer pools. Pre-amplified samples were diluted with $0.1 \times \text{TE}$ buffer (pH 8.0) and stored at -80°C until analysis. The miRNA profile was acquired using Human TaqMan Low-Density Array (TLDA) cards v.3 containing 750 unique miRNAs (ThermoFisher Scientific). All of the TLDA cards had the same lot number to minimize variation. Expression data were obtained using the ViiA 7 real-time PCR system and analyzed using QuantStudio software. Amplification plots were manually inspected and assays with poor or no amplification (undetectable) were excluded from further analysis ($n = 406$). A pre-specified criterion was that a miRNA needed to be present in at least 10 (15%) of the samples, so as to be included in further analyses. Data were normalized using the global mean normalization method (39). Data from this miRNA discovery profiling would be available upon reasonable request.

Technical Validation of miRNA by Individual qPCR

A total of 200 ng serum RNA was reverse transcribed with mature miRNA-specific stem-loop RT-primers using SuperScript III (Thermo Fisher Scientific). Subsequently, qPCR was performed on diluted cDNA using QuantiTect SYBR Green PCR master mix (Qiagen, Copenhagen, Denmark) as described previously (26) (oligos are listed in **Supplementary Table 1**). All reactions were performed in duplicate. The miRNA levels were normalized to the expression of miR-484, which showed minimal variation across samples and experimental groups according to the NormFinder (40) algorithm (**Supplementary Figure 1**). MiRNA-484 has been used by others as a reference and normalization miRNA (41). This also provided a validation of our TaqMan (TLDA) data using SYBR Green qPCR chemistry.

Statistical Analyses

Statistical analyses were performed using the Statistical Packages for Social Sciences (SPSS) vers. 24 or the statistical package R and

R-Studio vers. 3.1.3. A prior power analysis with the given sample size shows that we have a power of more than 90% to detect a fold change of 1.5 with a relative SD of 0.4 with a Student's *t*-test (estimated effect size, Cohen's *d*, 1.25).

TLDA miRNA relative levels were quantified by the $2^{-\Delta\Delta\text{Ct}}$ method. Validation of the relative expression of individual miRNAs was quantified by the standard curve method. Normal distribution was assessed by a Kolmogorov-Smirnov test. Logarithmic transformation was applied to the non-normally distributed data. Group means were compared by Student's *t*-test or one-way ANOVA with Tukey's *post-hoc* test (two-sided). Values were reported as mean \pm SD or medians (interquartile range) as appropriate. Pearson correlations were visualized using the R package *corrplot* (42). Partial Pearson correlations were performed to control for the effects of age and BMI. A volcano plot was plotted to display fold changes (\log_2) against statistical *t*-test *p*-values ($-\log_{10}$) for each miRNA in relation to PCOS women and Controls. To adjust for the potentially confounding effect of age and BMI, binary logistic regression analyses for the association between each of the miRNA and PCOS or multinomial logistic regression for the three different groups were carried out represented by the odds ratio (OR) and 95% confidence interval (CI).

A *p*-value of < 0.05 was considered statistically significant. Adjustment for multiple testing was not found applicable given the lack of independence of variables (43) [e.g., miRNAs show a high degree of correlation within groups (44)] in the dataset and the exploratory nature of the study. GraphPad Prism vers. 8 (GraphPad Inc., La Jolla, CA, U.S.A.) was used for figure preparation.

RESULTS

Demographics, Clinical and Biochemical Markers of the Study Population

Both PCOS women and Controls were well matched for age and BMI (**Table 1**). In the PCOS group FG scores, androgens, luteinizing hormone (LH) were significantly elevated (**Table 1**). The biochemical hyperandrogenic PCOS women were more insulin resistant ($p < 0.01$) compared to the normoandrogenic PCOS group. Furthermore, the incidence of MetS was higher in PCOS women with elevated serum free T ($p < 0.05$).

Human Serum miRNA Profiles by Array Analysis

We performed an extensive qPCR based profiling of 750 different miRNAs in serum from all 62 subjects in our cohort in order to identify dysregulated miRNAs in PCOS women. Among the predefined 750 miRNAs, we identified 303 miRNAs (40.4%) as robustly present in serum. The 10 most abundant serum miRNAs in the entire study population had similar levels with miR-518 species being most abundant among circulating miRNAs ($\text{C}_T \leq 10.0$, **Supplementary Table 2**). Analyzing the intercorrelation between the 50 most highly expressed miRNAs revealed that the majority ($n = 41$) of the miRNAs correlated with each other belonging either in one large or in one smaller cluster (**Supplementary Figure 2**). Moreover, we evaluated the

TABLE 1 | Baseline characteristics of study participants.

	Control	PCOS	<i>p</i>	Normo PCOS	Hyper PCOS	<i>p</i>
<i>N</i>	20	42		23	19	
Age	27 (7.5)	27 (6.3)	NS	29 (7)	27 (6)	NS
Height (cm)	166.9 ± 6	169.5 ± 6.1	NS	171.2 ± 6.4	167.3 ± 5.2	NS
Weight (kg)	71.3 (23.8)	72.3 (18.1)	NS	71.6 (15)	75 (16.2)	NS
Body Mass Index (kg/m ²)	25.0 (6.9)	24.4 (5.9)	NS	23.8 (4.7)	28.4 (6.2)	NS
Waist-to-hip ratio	0.8 ± 0.1	0.8 ± 0.1	NS	0.8 ± 0.1	0.8 ± 0.1	NS
Ferriman–Gallwey (FG) score	1.0 (1.0)	4.0 (6.3)	<0.01	4.0 (6.0)	5.0 (6.0)	<0.01 ^{a,b}
Total testosterone (T) (nmol/L)	1.1 (0.5)	2.4 (1.5)	<0.01	1.9 (1.1)	3.7 (2.3)	<0.01 ^{a,b,c}
Free testosterone (T) (nmol/L)	0.014 (0.005)	0.025 (0.045)	<0.01	0.020 (0.006)	0.066 (0.018)	<0.05 ^{a,b,c}
Sex hormone binding globulin (SHBG) (nmol/L)	71.0 (36.3)	65.5 (55.8)	NS	88.0 (53)	46.0 (36)	<0.01 ^{a,c}
Androstenedione (nmol/L)	4.4 (2.5)	7.7 (4.5)	<0.01	5.4 (2.5)	10.1 (4.3)	<0.01 ^{a,b,c}
Dehydroepiandrosterone sulfate (DHEAS) (nmol/L)	5,291 ± 1,949	5,959 ± 2,473	NS	4,642 ± 1,644	7,554 ± 2,393	<0.01 ^{a,c}
Follicle-stimulating hormone (FSH) (IU/L)	6.3 ± 1.9	5.6 ± 1.7	NS	5.7 ± 1.9	5.4 ± 1.5	NS
Luteinizing hormone (LH) (IU/L)	5 (3.8)	11.6 (5.9)	<0.01	10.8 (6.6)	12 (6.3)	<0.01 ^{a,b}
Estradiol (nmol/L)	0.19 (0.04)	0.2 (0.03)	NS	0.2 (0.12)	0.2 (0.01)	NS
Prolactin (mIU/L)	212.0 (132)	212.0 (135)	NS	237.0 (141)	209.0 (118)	NS
Thyroid stimulating hormone (TSH)	1.8 (1.2)	1.7 (1)	NS	1.7 (0.7)	1.5 (1.2)	NS
Alanine transaminase (ALAT) (u/L)	15.5 (10)	18 (16.5)	NS	17 (8)	22 (19)	NS
Fasting plasma glucose (mmol/L)	5.0 (0.5)	5.1 (0.5)	NS	5.1 (0.4)	5.2 (0.6)	NS
Fasting serum insulin (mU/L)	7.7 (5.5)	6.9 (8.1)	NS	6.2 (5.6)	8.8 (8.8)	<0.01 ^c
Fasting plasma C-peptide (pmol/L)	605(260)	560 (390)	NS	470 (270)	680 (390)	<0.05 ^{a,c}
HOMA-IR (mU·mmol·L ⁻²)	1.8 (1.3)	1.5 (1.9)	NS	1.3 (1.5)	2.1 (2.1)	<0.01 ^c
Total cholesterol (mmol/L)	4.4 (1.1)	4.3 (0.9)	NS	4.4 (1.3)	4.3 (0.7)	NS
LDL cholesterol (mmol/L)	2.6 ± 0.8	2.4 ± 0.7	NS	2.5 ± 0.7	2.4 ± 0.7	NS
HDL cholesterol (mmol/L)	1.6 (0.4)	1.5 (0.5)	NS	1.6 (0.5)	1.4 (0.4)	<0.05 ^{a,c}
Triglycerides (mmol/L)	0.6 (0.2)	0.7 (0.5)	NS	0.6 (0.3)	1.0 (0.8)	<0.05 ^{a,c}
Metabolic syndrome (yes/no)	1/20	7/35	NS	1/22	6/13	<0.05 [#]

Baseline characteristics of the study participants. Data presented as mean ± SD or as median (interquartile range) if not normally distributed. Biochemical hyperandrogenic (Hyper) and normoandrogenic (Normo) PCOS patients were defined based on a free T level above or below 0.034 nmol/L, respectively. HOMA-IR, homeostatic model assessment of insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, not significant.

^aSignificant difference between hyperandrogenic patients and Controls after Tukey post-hoc.

^bSignificant difference between normoandrogenic patients and Controls after Tukey post-hoc.

^cSignificant difference between hyperandrogenic patients and normoandrogenic after Tukey post-hoc.

[#]Significant difference between hyperandrogenic patients and both normoandrogenic PCOS women and Controls after Fisher's Exact test. *P* < 0.05 were consider significant.

variability of the miRNAs in the control women and in the entire sample set (**Supplementary Figure 3**). The clear majority of the circulating miRNAs had an inter-assay coefficient of variation (CV) of <5%; only 18 out of 303 miRNAs had a CV >5% (**Supplementary Figure 3**). Thus, although there is interpersonal variation in the levels of each miRNA, with few exceptions, the levels of each species of miRNA appears quite defined, at least in our specific cohort of PCOS women and Controls.

Circulating miRNAs Are Able to Differentiate Between PCOS Patients and Controls

The potential of each circulating miRNAs (*n* = 303) to differentiate between healthy Controls and women with PCOS

was evaluated and is illustrated using a Volcano plot (**Figure 1**). Three serum miRNAs (1.0% of detected miRNAs; miR-485-3p, miR-1290, and miR-7-1-3p) were significantly increased while eight miRNAs (2.6% of detected miRNAs; miR-21-3p, -139-3p, -572, -361-5p, -143-3p, -345-5p, -1276, and miR-22-5p) were significantly decreased in PCOS women compared with Controls (**Figure 1**). Half of the miRNAs showed more than an absolute fold difference of 1.8 between the two groups. As obesity amplifies and worsens the metabolic and reproductive abnormalities in PCOS and advanced age gradually decreases the severity of cardinal features of PCOS, data for the eleven significant miRNAs were adjusted for the confounding effects of age and BMI. Both miR-485-3p and miR-1290 remained significantly associated with increased odds of having PCOS (*p* = 0.02, OR 1.5, 95% CI: 1.1–2.2 and *p* = 0.02, OR 1.3, 95% CI: 1.0–1.8) with a 1.1 and 1.6 fold




FIGURE 1 | Volcano plot displaying differences in circulating miRNA levels between PCOS women and Controls. Volcano plot based on miRNA mean fold changes between PCOS patients vs. Control subjects. Open circles indicate significantly [$p < 0.05$; $-\log(p\text{-value})$ of -1.3 , dotted line] increased or decreased relative miRNA levels of each miRNA in PCOS patients compared to Control subjects.

increase observed in PCOS women compared to Controls (**Figures 2A,B**).

As can be seen in **Figures 2C–G**, miR-21-3p ($p = 0.004$, OR 0.6, 95% CI: 0.3–0.9), miR-139-3p ($p = 0.0004$, OR 0.5, 95% CI: 0.3–0.9), miR-361-5p ($p = 0.001$, OR 0.4, 95% CI: 0.2–0.9), miR-572 ($p = 0.005$, OR 0.3, 95% CI: 0.1–0.8), and miR-143-3p ($p = 0.01$, OR 0.3, 95% CI: 0.1–0.9) all remained significantly associated with decreased odds of having PCOS. All five miRNAs were decreased by 1.7-fold or more, except miR-143-3p, in PCOS patients compared to Controls. Levels of the remaining four miRNAs can be found in **Supplementary Figure 4**.

To confirm the results obtained by the arrays a technical validation was performed for miR-485-3p (**Supplementary Figure 5**). In the arrays, miR-485-3p was elevated in PCOS women (**Figure 2A**, $p = 0.004$). The individual qPCR showed that miR-485-3p was indeed significantly increased in PCOS patients compared with the Controls ($p < 0.001$).

Dysregulated Circulating miRNAs in PCOS Women Subsets


Evaluation of miRNAs defining the normoandrogenic and hyperandrogenic PCOS patient subsets and Controls showed that 20 miRNAs were expressed differently within the three groups after age and BMI correction (**Figure 3** and **Supplementary Figure 6**). Given that several of the miRNAs showed similar expressions and a high degree of correlation between individual miRNAs, a subset of these are shown in **Figures 3A–H**. In women with normal free T levels, miR-485-3p was found elevated by 1.3-fold compared to Controls ($p < 0.05$, **Figure 3A**). Despite also being increased in hyperandrogenic PCOS women, this

comparison was not significant. A gradual increase in miR-1290 levels ($p < 0.05$, **Figure 3B**) as well as a 2-fold increase of miR-20a-5p ($p < 0.05$, **Figure 3C**) were observed in the hyperandrogenic PCOS women. Circulating miR-139-3p was also significantly decreased in both PCOS subsets compared to healthy Controls with the more hyperandrogenic PCOS women displaying the largest reduction (1.9- vs. 1.7-fold, $p < 0.05$, **Figure 3D**). Normoandrogenic PCOS women and Controls had similar levels of miR-433-3p while it being 2-fold less abundant in hyperandrogenic PCOS patients compared to either group ($p < 0.05$ or $p < 0.01$, **Figure 3E**). In comparison to Controls, miR-361-5p decrease gradually the more hyperandrogenic the PCOS women were (2.9-fold, $p < 0.01$, **Figure 3F**). Both miR-34b-3p and miR-1225-3p were increased in normoandrogenic PCOS patient either compared to hyperandrogenic PCOS women or Controls ($p < 0.05$, **Figures 3G,H**).

The remaining dysregulated miRNAs between the two PCOS subsets and Controls, which were still significant after adjustments for BMI and age, are displayed in **Supplementary Figure 6**.

Circulating miRNAs Correlate With Androgens and Biochemical Markers of Metabolic Syndrome


The relationship between circulating miRNA, androgens and biochemical markers of MetS was explored by correlation analysis controlling for the effects of BMI and age in the entire cohort (**Table 2**). Hyperandrogenism (in the form of either total T, free T, DHEAS or androstenedione) was positively associated with miR-1290 (r range: 0.47–0.35) and miR-20a-5p



(*r* range: 0.39–0.30). In contrast, miR-139-3p (*r* range: −0.41 to 0.37), −433-3p (*r* range: −0.51 to 0.35), −361-5p (*r* range: −0.48 to 0.34), and −34b-3p (*r* = −0.43 to 0.29) correlated negatively with hyperandrogenism. Furthermore, SHBG, which is generally low in PCOS, was positively correlated with miR-361-5p (*r* = 0.37, *p* = 0.038) and miR-433-3p (*r* = 0.36, *p* = 0.013). Fasting glucose was modestly associated with miR-20a-5p (*r* = 0.32, *p* = 0.022). Both serum insulin (*r* = −0.50) and HOMA-IR (*r* = −0.50) levels correlated negatively with miR-1225-5p (*p* = 0.001). Biochemical markers of MetS such as total cholesterol, HDL cholesterol, and triglycerides were associated with miR-433-3p (*r* = 0.41, *p* = 0.005) and miR-361-5p (HDL: *r* = 0.39, *p* = 0.027, and triglycerides: *r* = −0.37, *p* = 0.036). Lastly, miR-1290 and HDL cholesterol (*r* = −0.28, *p* = 0.042) correlated with each other. Thus, we observed a multitude of correlations between levels of specific circulating miRNAs and features of biochemical hyperandrogenism and the MetS.

Diagnostic Capabilities of Circulating miRNA

The observed frequency of MetS was significantly higher in the hyperandrogenic PCOS patients, which led us to verify whether potential differences in these 20 circulating miRNAs (Figure 3 and Supplementary Figure 6) could be used to distinguish the presence of MetS in PCOS women. Initially, receiver operator characteristic (ROC) curves were constructed and area under the curve (AUC) values for each miRNA were evaluated (Supplementary Table 3). For PCOS women, as shown in Figure 4A, miR-361-5p was the best independent predictor of MetS (AUC 0.92, 95% CI 0.79–1.0) followed by miR-1225-3p (AUC 0.82, 95% CI 0.65–0.99) and miR-34b-3p (AUC 0.77, 95% CI 0.58–0.96). A biomarker panel was constructed using a combination of the three miRNAs and binary logistic regression analysis. The 3-miRNA panel had an AUC of 0.96 (95% CI 0.90–1.0) and correctly classified all of the seven cases of MetS found in the PCOS group.



Serum free T was significantly elevated in PCOS women with MetS compared to PCOS women without MetS [mean (SD):0.069 (0.034) vs. 0.036 (0.024), $p = 0.004$]. We therefore also investigated the ability of serum T to predict MetS among PCOS women. The discriminatory ability of serum free T alone in relation to MetS in PCOS women was found to be specific (100% specificity), but also to display a low sensitivity of just 14% yielding an AUC of 0.78 (95% CI 0.60–0.96) (Figure 4B). The low sensitivity was observed, because only six out of the twenty hyperandrogenic PCOS women had MetS. Addition of serum free T in the logistic regression model did not significantly improve the AUC of the model and was therefore not included in the combined model (data not shown). Further, the miRNA profile between the two PCOS subsets (normoandrogenic vs. hyperandrogenic) was markedly different (Supplementary Figure 7), which underlines the heterogeneity in phenotypes among women with PCOS.

DISCUSSION

To date, this is the largest explorative study of serum miRNA profiles in PCOS patients and Controls. Its major strength is the employment of comprehensive array measurements in all individual samples from the study population. Using this approach, we identified two (miR-485-3p and miR-1290) circulating miRNAs with increased levels and five miRNAs (miR-21-3p, -139-3p, -361-5p, -572, and -143-3p) with lower levels in PCOS patients compared to control subjects independent of age and BMI. Furthermore, twenty miRNAs; eight of which were further analyzed (miR-20a-5p, -34b-3p, -139-3p, -361-5p, -433-3p, -485-3p, -1225-3p, and miR-1290) had different levels between either the two PCOS subset or between healthy Controls and one of the PCOS subsets (Figure 3 and Supplementary Figure 6). Additionally, clinical variables related to PCOS, such as free T, DHEAS, and androstenedione were

TABLE 2 | Correlations between biochemical variables and miRNA levels.

Clinical variable	miRNAs	<i>r</i>	<i>r</i> adjusted	<i>p</i>	<i>p</i> adjusted
Total T	miR-1290	0.403	0.399	0.002	0.003
	miR-139-3p	-0.426	-0.410	0.003	0.005
	miR-361-5p	-0.369	-0.340	0.032	0.057
	miR-34b-3p	-0.295	-0.286	0.042	0.054
Free T	miR-1290	0.373	0.351	0.005	0.009
	miR-20a-5p	0.364	0.302	0.006	0.028
	miR-139-3p	-0.330	-0.368	0.023	0.013
	miR-433-3p	-0.492	-0.512	0.0004	0.0003
	miR-361-5p	-0.515	-0.461	0.002	0.008
SHBG	miR-20a-5p	-0.289	-0.153	0.031	0.269
	miR-433-3p	0.301	0.358	0.036	0.013
	miR-361-5p	0.419	0.369	0.014	0.038
DHEAS	miR-34b-3p	-0.412	-0.425	0.004	0.003
Androstenedione	miR-1290	0.493	0.468	0.0001	0.004
	miR-20a-5p	0.385	0.393	0.004	0.004
	miR-433-3p	-0.335	-0.353	0.02	0.016
	miR-361-5p	-0.465	-0.478	0.006	0.007
Fasting glucose	miR-20a-5p	0.273	0.317	0.046	0.022
	miR-139-3p	-0.306	-0.262	0.039	0.086
Fasting insulin	miR-20a-5p	0.326	0.177	0.016	0.209
	miR-361-5p	-0.458	-0.312	0.006	0.082
	miR-1225-3p	-0.424	-0.502	0.005	0.001
HOMA-IR	miR-20a-5p	0.347	0.212	0.01	0.132
	miR-361-5p	-0.470	-0.335	0.005	0.061
	miR-1225-3p	-0.427	-0.501	0.005	0.001
Total cholesterol	miR-433-3p	0.336	0.405	0.018	0.005
HDL cholesterol	miR-1290	-0.296	-0.280	0.028	0.042
	miR-361-5p	0.442	0.390	0.009	0.027
Triglycerides	miR-20a-5p	0.401	0.268	0.002	0.052
	miR-361-5p	-0.476	-0.372	0.004	0.036

Correlation between selected serum miRNAs and baseline characteristics. MiRNA levels (normalized to the global mean) were log₂ transformed prior to analysis. Some of the biochemical parameters were also log₂ transformed prior to analysis as described in Materials and Methods. Indicated Pearson correlation coefficients are significant at $p < 0.05$, p adjusted = Controlling for the effects of age and BMI using partial Pearson correlation analysis. T, Testosterone; SHBG, Sex hormone-binding globulin.

correlated with the miRNAs suggesting their involvement in the pathophysiology of PCOS and its intermediary phenotypes (Table 2). We also observed that five miRNAs (miR-20a-5p, 1225-3p, -433-3p, -1290, and -361-5p) were associated with either aberrant glucose homeostasis or dyslipidemia. Importantly, a 3-miRNA panel consisting of miR-361-5p, -1225-3p, and miR-34b-3p was able to discriminate between MetS in PCOS women independently of androgen status in terms of serum free T.

Since qPCR arrays were performed in all individuals, which to our knowledge has not been done before in relation to PCOS, we were able to determine that a high degree of correlation exists between individual miRNAs (absolute Pearson correlation coefficients ≥ 0.7 , Supplementary Figure 2) suggesting a




FIGURE 4 | Individual microRNAs are predictive of metabolic syndrome in PCOS women. Receiver operator characteristic curves based on microRNA levels (normalized to global mean). Shown are three microRNAs as well as a combination of these distinguishing between metabolic syndrome cases and those without in the PCOS group (A). Additionally, area under the curves (AUCs) for serum free testosterone compared to the 3-miRNA signature within the PCOS group are displayed (B). The corresponding AUCs and 95% CI: intervals can be found in Supplementary Table 3.

miRNA:miRNA network and potential co-regulation of certain miRNAs or a common cellular origin of most of the circulating miRNAs. Also, in our specific cohort of PCOS women and Controls, most of the miRNAs displayed a low degree of inter-individual variability, which allows for relatively good power to detect miRNAs that are different between PCOS and control women (Supplementary Figure 3). In recent years, miRNAs have gained increasing attention based on their application in biomarker studies and as much as 30 different serum miRNAs have been identified to be involved in PCOS (16–24), combined with an additional four miRNAs in whole blood (29), and miR-93 in plasma (25). However, only a few studies have aimed to identify/characterize miRNAs associating with PCOS subphenotypes.

It is well established that PCOS is associated with defects in insulin secretion and profound insulin resistance (45). The mitochondrial biogenesis master regulator; peroxisome

proliferator-activated receptor γ coactivator 1 α (PGC-1 α) is required to maintain insulin-mediated signaling as well as mitochondrial function and integrity, thus underscoring its importance in the development of insulin resistance (46). Reduced levels of PGC-1 α have been found in PCOS women (47). Of interest, miR-485-3p has been shown to target PGC-1 α (48); thus it could be speculated that increased levels of miR-485-3p in PCOS women could inhibit PGC-1 α and subsequently impart insulin resistance. Moreover, miR-378a-5p, increased in serum of hyperandrogenic PCOS patients (**Supplementary Figure 6B**), is located within the gene encoding PGC-1 β (PPARGC1B) and causes hepatic insulin resistance by targeting the catalytic subunit of PI3 kinase (49), while simultaneously opposing the actions of PGC-1 β (50), suggesting further links between PCOS associated miRNAs and insulin resistance.

Profiling of miRNAs in human follicular fluid identify miR-1290 among the highest expressed miRNAs (51) although not differentially expressed between PCOS women and controls as was observed in the current study. Increased circulating miR-1290 has been reported for various cancers (52, 53) as well as gestational diabetes (54) and non-alcoholic fatty liver disease (NAFLD) (55). Potential predicted targets of miR-1290 are the transforming growth factor β (TGF- β) 2 and 3 as well as the downstream mediators Smad-2, -5, -7, and -9. Dysregulated TGF- β signaling pathway in PCOS pathophysiology has been reported (56–59).

Encoded within the miR-17–92 cluster, miR-20 has been shown to modulate the TGF- β pathway, the E2F transcription family (E2F1–3), the insulin gene enhancer protein (Isl-1), the T-box 1 protein (Tbx1) reviewed by Mogilyansky and Rigoutsos (60); all of which have been linked to PCOS pathophysiology (61).

Out of the seven PCOS-specific miRNAs, miR-21; which was downregulated in our study, has been reported to be increased in serum from PCOS women (23). The observed discrepancy, could partly, be explained by the fact that the included PCOS women in the study by Jiang et al. (23) had a higher BMI compared to controls. Adding to this, obesity was shown by Murri et al. to increase the expression of whole blood miR-21 in PCOS women (29). In support of our findings, reduced serum miR-21 was observed in hyperandrogenic PCOS women, although not significant, by Naji et al. (62) and low plasma miR-21 was demonstrated in type 2 diabetic subjects (63).

Our work revealed a downregulated expression of miR-34b-3p in biochemical hyperandrogenic PCOS women compared to PCOS women with normal serum free T levels (**Figure 3**). A study on the clinical relevance of miR-34b-3p, although in relation to prostate cancer, revealed that miR-34b-3p could control transcription of the androgen receptor (AR) *in vitro*. Moreover, high tissue expression of AR protein correlated with low miR-34b-3p levels (64). Given the importance of androgens and the androgen receptor in the pathogenesis of PCOS (65), it could be speculated that the low expression of miR-34b-3p observed in the hyperandrogenic PCOS women could enhance expression of AR thereby resulting in dysregulated androgen metabolism. Our results provide a basis for pursuing studies on the functional consequence of altered miRNAs in terms of subphenotypes of PCOS.

Elevated circulating vascular endothelial growth factors (VEGF) may, partly contribute to the highly vascularized and dense hyperchogenic stroma observed in ovaries of PCOS women. Furthermore, insulin can stimulate VEGF secretion while high levels of VEGF have been associated with occurrence and severity of ovarian hyperstimulation syndrome (OHSS) in women with PCOS and negative conception rates augmenting its role in PCOS pathophysiology (66). Low levels of miR-361-5p in our PCOS women; lowest in hyperandrogenic PCOS women (**Figures 2, 3**), could contribute to increased levels of VEGF-A which is an identified target of miR-361-5p (67).

Prediabetic individuals presented with lower levels of circulating miR-572 compared to newly diagnosed type 2 diabetic patients, although not with lower levels than individuals with normal glucose tolerance (68). It could be speculated whether a decrease in miR-572, as observed in our study, could serve as a biomarker for early detection of prediabetes in PCOS women.

We here demonstrate that serum levels of miR-433-3p significantly differed between hyperandrogenic PCOS women and Controls and normoandrogenic PCOS women (**Figure 3**). A recent study in pancreatic β -cells showed that miR-433-3p had a protective effect toward glucose toxicity (69) thus low levels of miR-433-3p could contribute to the increased risk of type 2 diabetes observed in PCOS women.

To the best of our knowledge, no studies with relations to PCOS have found a mechanism by which elevated miR-1225-3p or decreased miR-139-3p could be involved in PCOS. Regardless of mammalian species, miR-143 is among the most predominate miRNAs expressed in the ovary (70). Dysregulated miR-143, in mouse models, has been implicated in obesity-associated insulin resistance (71), in the formation of primordial follicles (72) and progesterone release (73).

As stated earlier, miR-93 has received attention from several groups (25, 27, 62, 74). We observe that miR-93-3p is borderline decreased in PCOS women compared to Controls ($p = 0.051$) thus in contrast to increased circulating plasma levels of miR-93 isolated from PCOS women (25). At present, it is unclear whether differences in pre-analytic strategies, mainly normalization, account for the variable findings or whether these findings are due to differences in study populations.

The nature of the current study was to investigate the miRNA profile in serum. We do not know the pathophysiological actions or mechanisms that regulate the serum miRNA profile, nor the tissues from which circulating miRNAs originate. However, it is apparent that a varied tissue distribution of miRNAs exists. The miRNAs present in serum are the result of secretion of these into the circulation by various tissues and cells. Identification of their cellular origin can be difficult. Two studies have compiled a list of miRNA abundance and tissue-specific distribution (75, 76). Ludwig et al. investigated only tissues derived from male donors, which limits any evaluation of the contribution of the female reproductive tissues to the total miRNA pool found in serum (76). However, all of the miRNAs differentially expressed in our study could be identified in all of the tissues examined by Ludwig et al. with the exception of miR-720, miR-661, and miR-1225-3p (76). A possible explanation as to why miR-720 was not reported could be that it is not a *bonafide* miRNA, but a tRNA fragment

(77). When interpreting miRNA profiling results obtained from serum, it is likely that at least some of these may reflect a direct effect from blood cells. It would be very relevant to investigate the tissue source of these miRNAs, which possibly could be done by the capture of exosomes using tissue-specific surface markers.

Packaging of miRNAs into microvesicles, as a way to protect the miRNAs in the circulation but also contributing to intercellular signaling, has emerged as a new and interesting field of study. In this context, circulating platelet-derived microparticles were found elevated in both lean and obese women with PCOS compared with controls (78, 79) and these correlated with serum T. The increased concentration of microparticles has also been associated with HOMA-IR in PCOS subject (80). Moreover, the PCOS associated miR-485-3p was shown to be preferentially packaged into circulating exosomes (81).

Prevalence rates of MetS are higher in women with PCOS compared with the general female population. It is well known that MetS is associated with an increased risk of developing type 2 diabetes and most of these metabolic risk factors are present in PCOS as well. Abnormal levels of miRNAs in relation to MetS or to pathophysiological components hereof have been reported (82–84). Given the public health implications of MetS, early identification is warranted in order to target early interventions. Our three candidate miRNA signature (miR-361-5p, -1225-3p, and miR-34b-3p) had a 97.1% sensitivity and 85.7% specificity for identifying MetS in PCOS. Additionally, serum free T levels are higher in PCOS with MetS compared to PCOS women without MetS (85). Interestingly, serum free T did not increase the AUC, when combined with miRNAs thus there is no significant additional influence of serum free T compared to the 3-miRNA signature alone. We acknowledge that the ROC curve evaluation of the prediction model in the PCOS women was limited by sample size with a lower than expected frequency of MetS in these women, although it still reached statistical significance. Clearly, the discriminatory utility of the 3-miRNA signature should be validated in larger cohorts.

While the clinical usefulness of measuring a circulating miRNA for a PCOS related diagnostic purpose is currently limited, the measurement of miRNAs in a clinical or ambulatory setting using fast microfluidic nanoparticle-based devices is an area of intense research (86) possibly enabling future use of miRNAs for rapid tests. Our study adds novel information to the growing body of evidence indicating a markedly different profile of circulating miRNAs in diseases with elements of metabolic dysfunction (PCOS, impaired glucose tolerance, obesity, non-alcoholic fatty liver disease) (87, 88). Mapping out the miRNAs altered during specific conditions could provide vital cues to identifying their role as biomarkers and/or modulators of the disease process. Future studies will deliver key indications of common and separate pathways to metabolic disease.

In conclusion, we here report comprehensive profiling of miRNAs in serum of PCOS patients and show that PCOS patients have a profile of miRNAs deviating from Controls. Moreover, our data demonstrate that the miRNA profile is specific to subgroups of patients with PCOS: Normoandrogenic PCOS women have circulating miRNAs that cluster differently

compared with hyperandrogenic PCOS women. In addition, a three-candidate-miRNA biomarker signature can predict which women among PCOS sub-phenotypes (based on normal and increased free T levels) have a predisposition for developing MetS. It will be relevant to extend these findings to search for miRNAs related to fertility treatment outcomes.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Local Scientific Ethical Committee of Region Zealand, DK (approval no. SJ-156). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

AS, PU, MW, AE, and LD: study conception, design and interpretation of data, and drafting of the manuscript. NS, JG, GM, GJ, RM, AJ, and AH: contribution to figure creation, analysis of data and discussion. All authors read and approved the final manuscript.

FUNDING

This study was supported by a Merck Serono Grant for Fertility Innovation to MW, AE, and LD, a doctoral research grant from the Danish Diabetes Academy supported by the Novo Nordisk Foundation and from Roskilde University to AS, and grants from Region Zealand (Region Sjællands Forskningsfond) to PU and AE. Grants from ReproUnion, co-financed by European Union and Interreg program V Øresund-Kattegat-Skagerak to PU. An EFSD Albert Renold travel fellowship to NS and AS. The Postdoctoral Fellowship Scheme from the Chinese University of Hong Kong and RGC General Research Fund (ref. 14110415) to GJ and RM. A JDRF Australia Career Development Fellowship and a visiting professorship from the Danish Diabetes Academy to AH. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

ACKNOWLEDGMENTS

The authors wish to thank Christa Persson, Roskilde University for excellent technical expertise and help.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmed.2019.00242/full#supplementary-material>

REFERENCES

- Day FR, Hinds DA, Tung JY, Stolk L, Styrkarsdottir U, Saxena R, et al. Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. *Nat Commun.* (2015) 6:1–7. doi: 10.1038/ncomms9464
- Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. *Hum Reprod.* (2012) 27:3067–73. doi: 10.1093/humrep/des232
- Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. *Polycystic Ovary Syndrome*. Boston, MA: Blackwell Scientific Publication (1992). p. 377–84.
- Fauser BCJM, Azziz R, Tarlatzis R, Dunaif A, Ibanez L, Pugeat M, et al. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril.* (2004) 81:19–25. doi: 10.1016/j.fertnstert.2003.10.004
- Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. *J Clin Endocrinol Metab.* (2006) 91:4237–45. doi: 10.1210/jc.2006-0178
- Wehr E, Möller R, Horejsi R, Giuliani A, Kopera D, Schweighofer N, et al. Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndrome. *Wien Klin Wochenschr.* (2009) 121:262–9. doi: 10.1007/s00508-009-1162-2
- Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. *Hum Reprod Update.* (2004) 10:107–17. doi: 10.1093/humupd/dmh010
- Lerchbaum E, Schwetz V, Rabe T, Giuliani A, Obermayer-Pietsch B. Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype. *PLoS ONE.* (2014) 9:e108263. doi: 10.1371/journal.pone.0108263
- Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. *J Clin Endocrinol Metab.* (2006) 91:3922–7. doi: 10.1210/jc.2006-1054
- Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. *Eur J Endocrinol.* (2014) 171:P1–29. doi: 10.1530/EJE-14-0253
- Ohnemus U, Uenal M, Inzunza J, Gustafsson JÅ, Paus R. The hair follicle as an estrogen target and source. *Endocr Rev.* (2006) 27:677–706. doi: 10.1210/er.2006-0020
- Legro RS, Schlaff WD, Diamond MP, Coutifaris C, Casson PR, Brzyski RG, et al. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. *J Clin Endocrinol Metab.* (2010) 95:5305–13. doi: 10.1210/jc.2010-1123
- Albu A, Radian S, Fica S, Barbu CG. Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients. *Endocrine.* (2015) 48:696–704. doi: 10.1007/s12020-014-0340-9
- Vienberg S, Geiger J, Madsen S, Dalgaard LT. MicroRNAs in metabolism. *Acta Physiol.* (2017) 219:346–61. doi: 10.1111/apha.12681
- Sørensen AE, Udesen PB, Wissing ML, Englund ALM, Dalgaard LT. MicroRNAs related to androgen metabolism and polycystic ovary syndrome. *Chem Biol Interact.* (2016) 259:8–16. doi: 10.1016/j.cbi.2016.06.008
- Long W, Zhao C, Ji C, Ding H, Cui Y, Guo X, et al. Characterization of serum microRNAs profile of PCOS and identification of novel non-invasive biomarkers. *Cell Physiol Biochem.* (2014) 33:1304–15. doi: 10.1159/000358698
- Ding C-F, Chen W-Q, Zhu Y-T, Bo Y-L, Hu H-M, Zheng R-H. Circulating microRNAs in patients with polycystic ovary syndrome. *Hum Fertil.* (2014) 18:22–9. doi: 10.3109/14647273.2014.956811
- Kyeong Song D, Sung YA, Lee H. The role of serum microRNA-6767-5p as a biomarker for the diagnosis of polycystic ovary syndrome. *PLoS ONE.* (2016) 11:1–12. doi: 10.1371/journal.pone.0163756
- Xiong W, Lin Y, Xu L, Tamadon A, Zou S, Tian F, et al. Circulatory microRNA 23a and microRNA 23b and polycystic ovary syndrome (PCOS): the effects of body mass index and sex hormones in an Eastern Han Chinese population. *J Ovarian Res.* (2017) 10:1–11. doi: 10.1186/s13048-016-0298-8
- Eisenberg I, Nahmias N, Novoselsky Persky M, Greenfield C, Goldman-Wohl D, Hurwitz A, et al. Elevated circulating micro-ribonucleic acid (miRNA)-200b and miRNA-429 levels in anovulatory women. *Fertil Steril.* (2017) 107:269–75. doi: 10.1016/j.fertnstert.2016.10.003
- Naji M, Nekoonam S, Aleyasin A, Arefian E, Mahdian R, Azizi E, et al. Expression of miR-15a, miR-145, and miR-182 in granulosa-lutein cells, follicular fluid, and serum of women with polycystic ovary syndrome (PCOS). *Arch Gynecol Obstet.* (2018) 297:221–31. doi: 10.1007/s00404-017-4570-y
- Jiang L, Huang J, Chen Y, Yang Y, Li R, Li Y, et al. Identification of several circulating microRNAs from a genome-wide circulating microRNA expression profile as potential biomarkers for impaired glucose metabolism in polycystic ovarian syndrome. *Endocrine.* (2016) 53:280–90. doi: 10.1007/s12020-016-0878-9
- Jiang L, Li W, Wu M, Cao S. Circulating miRNA-21 as a biomarker predicts polycystic ovary syndrome (PCOS) in patients. *Clin Lab.* (2015) 61:1009–15. doi: 10.7754/Clin.Lab.2015.150122
- Murri M, Insenser M, Fernández-Durán E, San-Millán JL, Luque-Ramírez M, Escobar-Morreale HF. Non-targeted profiling of circulating microRNAs in women with polycystic ovary syndrome (PCOS): effects of obesity and sex hormones. *Metabolism.* (2018) 86:49–60. doi: 10.1016/j.metabol.2018.01.011
- Sathyapalan T, David R, Gooderham NJ, Atkin SL. Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis. *Sci Rep.* (2015) 5:16890. doi: 10.1038/srep16890
- Sørensen AE, Wissing ML, Englund ALM, Dalgaard LT. MicroRNA species in follicular fluid associating with polycystic ovary syndrome and related intermediary phenotypes. *J Clin Endocrinol Metab.* (2016) 101:1579–89. doi: 10.1210/jc.2015-3588
- Chen Y-H, Heneidi S, Lee J-M, Layman LC, Stepp DW, Gamboa GM, et al. miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. *Diabetes.* (2013) 62:2278–86. doi: 10.2337/db12-0963
- Jiang L, Huang J, Li L, Chen Y, Chen X, Zhao X, et al. MicroRNA-93 promotes ovarian granulosa cells proliferation through targeting CDKN1A in polycystic ovarian syndrome. *J Clin Endocrinol Metab.* (2015) 100:E729–38. doi: 10.1210/jc.2014-3827
- Murri M, Insenser M, Fernández-Durán E, San-Millán JL, Escobar-Morreale HF. Effects of polycystic ovary syndrome (PCOS), sex hormones, and obesity on circulating miRNA-21, miRNA-27b, miRNA-103, and miRNA-155 expression. *J Clin Endocrinol Metab.* (2013) 98:E1835–44. doi: 10.1210/jc.2013-2218
- Mase Y, Ishibashi O, Ishikawa T, Takizawa T, Kiguchi K, Ohba T, et al. MiR-21 is enriched in the RNA-induced silencing complex and targets COL4A1 in human granulosa cell lines. *Reprod Sci.* (2012) 19:1030–40. doi: 10.1177/1933719112442245
- Carletti MZ, Fiedler SD, Christenson LK. MicroRNA 21 blocks apoptosis in mouse periovulatory granulosa cells. *Biol Reprod.* (2010) 83:286–95. doi: 10.1095/biolreprod.109.081448
- Zhao C, Liu X, Shi Z, Zhang J, Zhang J, Jia X, et al. Role of serum miRNAs in the prediction of ovarian hyperstimulation syndrome in polycystic ovarian syndrome patients. *Cell Physiol Biochem.* (2015) 35:1086–94. doi: 10.1159/000373934
- Vejledning L. Testosteron frit;P. KBA. (2015) 33:981–1030. Available online at: <http://lmv.regionsjaelland.dk/KB/dokument.asp?DokID=290987>
- Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M. Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. *J Clin Endocrinol Metab.* (2014) 99:2584–91. doi: 10.1210/jc.2014-1135
- Wissing ML, Bjerre MR, Olesen AIG, Hoest T, Mikkelsen AL. Impact of PCOS on early embryo cleavage kinetics. *Reprod Biomed Online.* (2014) 28:508–14. doi: 10.1016/j.rbmo.2013.11.017
- Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab.* (1999) 84:3666–72. doi: 10.1210/jc.84.10.3666
- Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome : an endocrine

- society clinical practice guideline. *J Clin Endocrinol Metab.* (2013) 98:4565–92. doi: 10.1210/jc.2013-2350
38. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JJ, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention. *Circulation.* (2009) 120:1640–5. doi: 10.1161/CIRCULATIONAHA.109.192644
 39. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RT-qPCR data normalization. *Genome Biol.* (2009) 10:R64. doi: 10.1186/gb-2009-10-6-r64
 40. Andersen CL, Jensen JL, Ørntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. *Cancer Res.* (2004) 64:5245–50. doi: 10.1158/0008-5472.CAN-04-0496
 41. Marabita F, De Candia P, Torri A, Tegnér J, Abrignani S, Rossi RL. Normalization of circulating microRNA expression data obtained by quantitative real-time RT-PCR. *Brief Bioinform.* (2016) 17:204–12. doi: 10.1093/bib/bbv056
 42. Wei T, Simko V. *R Package Corrplot: Visualization of a Correlation Matrix, Version 0.84* (2017).
 43. McDonald JH. *Handbook of Biological Statistics*. 3rd ed. Baltimore: Sparky House Publishing (2014).
 44. Chaulk SG, Ebhardt HA, Fahlman RP. Correlations of microRNA:microRNA expression patterns reveal insights into microRNA clusters and global microRNA expression patterns. *Mol Biosyst.* (2016) 12:110–9. doi: 10.1039/C5MB00415B
 45. Diamanti-Kandaraki E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocr Rev.* (2012) 33:981–1030. doi: 10.1210/er.2011-1034
 46. Pagel-Langenickel I, Bao J, Joseph JJ, Schwartz DR, Mantell BS, Xu X, et al. PGC-1 α integrates insulin signaling, mitochondrial regulation, and bioenergetic function in skeletal muscle. *J Biol Chem.* (2008) 283:22464–72. doi: 10.1074/jbc.M800842200
 47. Skov V, Glinborg D, Knudsen S, Jensen T, Kruse TA, Tan Q, et al. Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. *Diabetes.* (2007) 56:2349–55. doi: 10.2337/db07-0275
 48. Lou C, Xiao M, Cheng S, Lu X, Jia S, Ren Y, et al. MiR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1 α expression. *Cell Death Dis.* (2016) 7:e2159. doi: 10.1038/cddis.2016.27
 49. Liu W, Cao H, Ye C, Chang C, Lu M, Jing Y, et al. Hepatic miR-378 targets p110 α and controls glucose and lipid homeostasis by modulating hepatic insulin signalling. *Nat Commun.* (2014) 5:5684. doi: 10.1038/ncomms6684
 50. Zhang T, Duan J, Zhang L, Li Z, Steer CJ, Yan G, et al. LXR α promotes hepatosteatosis in part through activation of microRNA-378 transcription and inhibition of Ppargc1 β expression. *Hepatology.* (2019) 69:1488–503. doi: 10.1002/hep.30301
 51. Sang Q, Yao Z, Wang HH, Feng R, Zhao X, Xing Q, et al. Identification of microRNAs in human follicular fluid: characterization of microRNAs that govern steroidogenesis *in vitro* and are associated with polycystic ovary syndrome *in vivo*. *J Clin Endocrinol Metab.* (2013) 98:3068–79. doi: 10.1210/jc.2013-1715
 52. Kobayashi M, Sawada K, Nakamura K, Yoshimura A, Miyamoto M, Shimizu A, et al. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types. *J Ovarian Res.* (2018) 11:81. doi: 10.1186/s13048-018-0458-0
 53. Tavano F, Gioffreda D, Valvano MR, Palmieri O, Tardio M, Latiano TP, et al. Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer. *Sci Rep.* (2018) 8:16389. doi: 10.1038/s41598-018-34597-z
 54. Lamadrid-Romero M, Solís KH, Cruz-Reséndiz MS, Pérez JE, Díaz NF, Flores-Herrera H, et al. Central nervous system development-related microRNAs levels increase in the serum of gestational diabetic women during the first trimester of pregnancy. *Neurosci Res.* (2018) 130:8–22. doi: 10.1016/j.neures.2017.08.003
 55. Tan Y, Ge G, Pan T, Wen D, Gan J. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. *PLoS ONE.* (2014) 9:e105192. doi: 10.1371/journal.pone.0105192
 56. Haouzi D, Assou S, Monzo C, Vincens C, Dechaud H, Hamamah S. Altered gene expression profile in cumulus cells of mature MII oocytes from patients with polycystic ovary syndrome. *Hum Reprod.* (2012) 27:3523–30. doi: 10.1093/humrep/des325
 57. Raja-Khan N, Urbanek M, Rodgers RJ, Legro RS. The role of TGF- β in polycystic ovary syndrome. *Reprod Sci.* (2014) 21:20–31. doi: 10.1177/1933719113485294
 58. Li Q, Pangas SA, Jorgez CJ, Graff JM, Weinstein M, Matzuk MM. Redundant roles of SMAD2 and SMAD3 in ovarian granulosa cells *in vivo*. *Mol Cell Biol.* (2008) 28:7001–11. doi: 10.1128/MCB.00732-08
 59. Tomic D, Miller KP, Kenny HA, Woodruff TK, Hoyer P, Flaws JA. Ovarian follicle development requires Smad3. *Mol Endocrinol.* (2004) 18:2224–40. doi: 10.1210/me.2003-0414
 60. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. *Cell Death Differ.* (2013) 20:1603–14. doi: 10.1038/cdd.2013.125
 61. Yin M, Wang X, Yao G, Lu M, Liang M, Sun Y, et al. Transactivation of miR-320 by miR-383 regulates granulosa cell functions by targeting E2F1 and SF-1. *J Biol Chem.* (2014) 289:18239–57. doi: 10.1074/jbc.M113.546044
 62. Naji M, Aleyasin A, Nekoonam S, Arefian E, Mahdian R, Amidi F. Differential expression of miR-93 and miR-21 in granulosa cells and follicular fluid of polycystic ovary syndrome associating with different phenotypes. *Sci Rep.* (2017) 7:14671. doi: 10.1038/s41598-017-13250-1
 63. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. Plasma MicroRNA profiling reveals loss of endothelial MiR-126 and other MicroRNAs in type 2 diabetes. *Circ Res.* (2010) 107:810–7. doi: 10.1161/CIRCRESAHA.110.226357
 64. Shiina M, Hashimoto Y, Kato T, Yamamura S, Tanaka Y, Majid S, et al. Differential expression of miR-34b and androgen receptor pathway regulate prostate cancer aggressiveness between African-Americans and Caucasians. *Oncotarget.* (2017) 8:8356–68. doi: 10.18632/oncotarget.14198
 65. Wang F, Pan J, Liu Y, Meng Q, Lv P, Qu F, et al. Alternative splicing of the androgen receptor in polycystic ovary syndrome. *Proc Natl Acad Sci USA.* (2015) 112:4743–8. doi: 10.1073/pnas.1418216112
 66. Peitsidis P, Agrawal R. Role of vascular endothelial growth factor in women with PCO and PCOS: a systematic review. *Reprod Biomed Online.* (2010) 20:444–52. doi: 10.1016/j.rbmo.2010.01.007
 67. Kanitz A, Imig J, Dziunycz PJ, Primorac A, Galgano A, Hofbauer GFL, et al. The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma. *PLoS ONE.* (2012) 7:e49568. doi: 10.1371/journal.pone.0049568
 68. Yan S, Wang T, Huang S, Di Y, Huang Y, Liu X, et al. Differential expression of microRNAs in plasma of patients with prediabetes and newly diagnosed type 2 diabetes. *Acta Diabetol.* (2016) 53:693–702. doi: 10.1007/s00592-016-0837-1
 69. Wang M. miR-433 protects pancreatic β cell growth in high-glucose conditions. *Mol Med Rep.* (2017) 16:2604–10. doi: 10.3892/mmr.2017.6925
 70. Hossain MM, Sohel MMH, Schellander K, Tesfaye D. Characterization and importance of microRNAs in mammalian gonadal functions. *Cell Tissue Res.* (2012). 349:679–90. doi: 10.1007/s00441-012-1469-6
 71. Jordan SD, Krüger M, Willmes DM, Redemann N, Wunderlich FT, Brönneke HS, et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. *Nat Cell Biol.* (2011) 13:434–46. doi: 10.1038/ncb2211
 72. Zhang J, Ji X, Zhou D, Li Y, Lin J, Liu J, et al. miR-143 is critical for the formation of primordial follicles in mice. *Front Biosci.* (2013) 1:588–97. doi: 10.2741/4122
 73. Sirotkin A V, Ovcharenko D, Grossmann R, Lauková M, Mlynček M. Identification of microRNAs controlling human ovarian cell steroidogenesis via a genome-scale screen. *J Cell Physiol.* (2009) 219:415–20. doi: 10.1002/jcp.21689
 74. Wu H-L, Heneidi S, Chuang T-Y, Diamond MP, Layman LC, Azziz R, et al. The expression of the miR-25/93/106b family of micro-RNAs in the adipose tissue of women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* (2014) 99:E2754–61. doi: 10.1210/jc.2013-4435

75. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. *Cell*. (2007) 129:1401–14. doi: 10.1016/j.cell.2007.04.040
76. Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, et al. Distribution of miRNA expression across human tissues. *Nucleic Acids Res*. (2016) 44:3865–77. doi: 10.1093/nar/gkw116
77. Schopman NCT, Heynen S, Haasnoot J, Berkhout B. A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. *RNA Biol*. (2010) 7:573–6. doi: 10.4161/rna.7.5.13141
78. Koiou E, Tziomalos K, Katsikis I, Kalaitzakis E, Kandaraki EA, Tsourdi EA, et al. Circulating platelet-derived microparticles are elevated in women with polycystic ovary syndrome diagnosed with the 1990 criteria and correlate with serum testosterone levels. *Eur J Endocrinol*. (2011) 165:63–8. doi: 10.1530/EJE-11-0144
79. Koiou E, Tziomalos K, Katsikis I, Papadakis E, Kandaraki EA, Panidis D. Platelet-derived microparticles in overweight/obese women with the polycystic ovary syndrome. *Gynecol Endocrinol*. (2013) 29:250–3. doi: 10.3109/09513590.2012.743005
80. Willis GR, Connolly K, Ladell K, Davies TS, Guschina IA, Ramji D, et al. Young women with polycystic ovary syndrome have raised levels of circulating annexin V-positive platelet microparticles. *Hum Reprod*. (2014) 29:2756–63. doi: 10.1093/humrep/deu281
81. Ebrahimkhani S, Vafaei F, Hallal S, Wei H, Lee MYT, Young PE, et al. Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis. *NPJ Precis Oncol*. (2018) 2:28. doi: 10.1038/s41698-018-0071-0
82. Goguet-Rubio P, Klug RL, Sharma DL, Srikanthan K, Puri N, Lakhani VH, et al. Existence of a strong correlation of biomarkers and mirna in females with metabolic syndrome and obesity in a population of West Virginia. *Int J Med Sci*. (2017) 14:543–53. doi: 10.7150/ijms.18988
83. Karolina DS, Tavintharan S, Armugam A, Sepramaniam S, Pek SLT, Wong MTK, et al. Circulating miRNA profiles in patients with metabolic syndrome. *J Clin Endocrinol Metab*. (2012) 97:E2271–6. doi: 10.1210/jc.2012-1996
84. Wang YT, Tsai PC, Liao YC, Hsu CY, Juo SHH. Circulating microRNAs have a sex-specific association with metabolic syndrome. *J Biomed Sci*. (2013) 20:72. doi: 10.1186/1423-0127-20-72
85. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab*. (2005) 90:1929–35. doi: 10.1210/jc.2004-1045
86. Wang YH, He LL, Huang KJ, Chen YX, Wang SY, Liu ZH, et al. Recent advances in nanomaterial-based electrochemical and optical sensing platforms for microRNA assays. *Analyst*. (2019) 144:2849–66. doi: 10.1039/C9AN00081J
87. Manning P, Munasinghe PE, Papannarao JB, Gray AR, Sutherland W, Katara R. Acute weight loss restores dysregulated circulating microRNAs in individuals who are obese. *J Clin Endocrinol Metab*. (2019) 104:1239–48. doi: 10.1210/jc.2018-00684
88. Liu CH, Ampuero J, Gil-Gómez A, Montero-Vallejo R, Rojas Á, Muñoz-Hernández R, et al. miRNAs in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. *J Hepatol*. (2018) 69:1335–48. doi: 10.1016/j.jhep.2018.08.008

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Sørensen, Udesen, Maciag, Geiger, Saliiani, Januszewski, Jiang, Ma, Hardikar, Wissing, Englund and Dalgaard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.